128 related articles for article (PubMed ID: 7885370)
1. Cytogenetic study of tuberculosis patients before and after tuberculostatic drug treatment.
Ekmekçi A; Sayli A
Mutat Res; 1995 Apr; 334(2):175-83. PubMed ID: 7885370
[TBL] [Abstract][Full Text] [Related]
2. Chromosomal aberrations in tuberculosis patients before and after treatment with short-term chemotherapy.
Rac VV; Gupta EV; Thomas IM
Mutat Res; 1991 Jan; 259(1):13-9. PubMed ID: 1988820
[TBL] [Abstract][Full Text] [Related]
3. [Side effects of various combinations of rifampin and isoniazid with ethambutol or streptomycin and pyrazinamide in short-term chemotherapy of newly-detected pulmonary tuberculosis].
Zierski M; Bek E
Pneumonol Pol; 1980 Jul; 48(7):469-79. PubMed ID: 7433146
[No Abstract] [Full Text] [Related]
4. Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council.
Am Rev Respir Dis; 1991 Apr; 143(4 Pt 1):707-12. PubMed ID: 1901200
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy.
Namasivayam S; Maiga M; Yuan W; Thovarai V; Costa DL; Mittereder LR; Wipperman MF; Glickman MS; Dzutsev A; Trinchieri G; Sher A
Microbiome; 2017 Jul; 5(1):71. PubMed ID: 28683818
[TBL] [Abstract][Full Text] [Related]
6. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Hong Kong Chest Service/British Medical Research Council.
Am Rev Respir Dis; 1991 Apr; 143(4 Pt 1):700-6. PubMed ID: 1901199
[TBL] [Abstract][Full Text] [Related]
7. Cytogenetic effects of chemotherapy with three combinations of anti-tubercular drugs involving isoniazid, thiacetazone, para-aminosalicylic acid and streptomycin on human lymphocytes: chromosome aberrations, sister chromatid exchanges and mitotic index.
Jaju M; Jaju M; Ahuja YR
Hum Genet; 1983; 64(1):42-9. PubMed ID: 6192073
[TBL] [Abstract][Full Text] [Related]
8. Assessment of a combined preparation of isoniazid, rifampicin and pyrazinamide (Rifater) in the initial phase of chemotherapy in three 6-month regimens for smear-positive pulmonary tuberculosis: a five-year follow-up report.
Teo SK
Int J Tuberc Lung Dis; 1999 Feb; 3(2):126-32. PubMed ID: 10091877
[TBL] [Abstract][Full Text] [Related]
9. Incidence of chromosomal aberrations in patients under combined tuberculostatic chemotherapy.
Roman IC; Vainer E; Socosan I; Drăghicescu T
Hum Genet; 1983; 63(2):191-2. PubMed ID: 6840764
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy of 6-month therapy with isoniazid and rifampin compared with isoniazid, rifampin, and pyrazinamide treatment for pleural tuberculosis.
García-Rodríguez JF; Valcarce-Pardeiro N; Álvarez-Díaz H; Mariño-Callejo A
Eur J Clin Microbiol Infect Dis; 2019 Nov; 38(11):2121-2126. PubMed ID: 31377953
[TBL] [Abstract][Full Text] [Related]
11. Antituberculous therapy and acute liver function.
Bourke SJ; White J; Stenton SC; Hendrick DJ
Lancet; 1995 May; 345(8958):1171-2. PubMed ID: 7786347
[No Abstract] [Full Text] [Related]
12. [Therapy of tuberculosis in the adult].
Schrappe M; Wassermann K; Kroegel C
Med Klin (Munich); 1995 Apr; 90(4):229-30. PubMed ID: 7776936
[No Abstract] [Full Text] [Related]
13. Further study on the cytogenetic effects of combined chemotherapy with isoniazid and para-aminosalicylic acid on human lymphocytes in vivo: sister chromatid exchanges, chromosome aberrations in first-division metaphases, cell growth kinetics, and mitotic index.
Jaju M; Jaju M; Ahuja YR
Environ Mutagen; 1983; 5(6):847-57. PubMed ID: 6653505
[TBL] [Abstract][Full Text] [Related]
14. Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis.
Am Rev Respir Dis; 1979 Apr; 119(4):579-85. PubMed ID: 375787
[TBL] [Abstract][Full Text] [Related]
15. Antituberculous therapy and acute liver function.
Ong EL
Lancet; 1995 May; 345(8958):1171. PubMed ID: 7723557
[No Abstract] [Full Text] [Related]
16. Olfactory disturbance related to pyrazinamide.
Tsou CC; Chien JY
QJM; 2014 Mar; 107(3):217-8. PubMed ID: 24023071
[No Abstract] [Full Text] [Related]
17. [Hepatic functional changes induced by the combined use of isoniazid, pyrazinamide and rifampicin in the treatment of pulmonary tuberculosis].
de Souza AF; de Oliveira e Silva A; Baldi J; de Souza TN; Rizzo PM
Arq Gastroenterol; 1996; 33(4):194-200. PubMed ID: 9302332
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis.
Schaberg T; Rebhan K; Lode H
Eur Respir J; 1996 Oct; 9(10):2026-30. PubMed ID: 8902462
[TBL] [Abstract][Full Text] [Related]
19. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group.
Gordin F; Chaisson RE; Matts JP; Miller C; de Lourdes Garcia M; Hafner R; Valdespino JL; Coberly J; Schechter M; Klukowicz AJ; Barry MA; O'Brien RJ
JAMA; 2000 Mar; 283(11):1445-50. PubMed ID: 10732934
[TBL] [Abstract][Full Text] [Related]
20. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
Wada M
Kekkaku; 2001 Jan; 76(1):33-43. PubMed ID: 11211781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
